PROCEPT BioRobotics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
July 27, 2023 at 07:10 am
Share
PROCEPT BioRobotics Corporation reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 33.1 million compared to USD 16.69 million a year ago. Net loss was USD 25.29 million compared to USD 19.18 million a year ago. Basic loss per share from continuing operations was USD 0.56 compared to USD 0.43 a year ago.
For the six months, sales was USD 57.51 million compared to USD 30.89 million a year ago. Net loss was USD 53.77 million compared to USD 36.37 million a year ago. Basic loss per share from continuing operations was USD 1.19 compared to USD 0.82 a year ago.
PROCEPT BioRobotics Corporation is a surgical robotics company, which is focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures and sells the AquaBeam Robotic System, which is an image-guided surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). The AquaBeam Robotic System employs a single-use disposable handpiece to deliver the Companyâs proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The Company designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, (LUTS), due to BPH that are independent of prostate size and shape or surgeon experience.
PROCEPT BIOROBOTICS CORPORATION 
